At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
LY900014 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Assess the Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy
In Brief
A Phase 1 clinical trial evaluating LY900014 and Insulin Lispro (Humalog) for Diabetes Mellitus, Type 1. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
This study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes LY900014, a new blood sugar lowering insulin, and its effect on blood sugar levels when it is delivered via an insulin pump. Side effects and tolerability will be documented. The study will last about 4 to 11 weeks for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartFeb 2017
Primary CompletionJun 2017
TodayJul 2026
First PostedFeb 17, 2017
Enrollment StartFeb 23, 2017
Primary CompletionJun 19, 2017
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 9.4 years ago
Interventions
LY900014drug
Administered subcutaneously (SC)
Insulin Lispro (Humalog)drug
Administered SC